
The 'Week in Review' - 16 February
It was not an easy or enjoyable decision, but the stakes are very high for Australian patients, given the apparent risks to the future of funded access to health technologies. We also discuss Senate E...
16 Feb 202429min

HTA Review options paper interview - 31 January
With just nine days remaining for stakeholders to submit their feedback on the Health Technology Assessment Review options paper, patients must have access to all pertinent information. BioPharmaDispa...
13 Feb 202431min

The 'Week in Review' - 9 February
The 'Swiss cheese' theory might explain why history is constantly repeating itself and why action is required to avoid the worst aspects of the proposals in the HTA Review options paper.
9 Feb 202427min

The 'Week in Review' - 2 February
We are back for 2024 with no end of issues to discuss, starting with the HTA review options paper and the coincidence of many reviews and processes delivering outcomes just ahead of the May Budget.
2 Feb 202441min

The 'End of Year Review' - 19 December
Looking ahead, the industry needs to find a framework for challenging the government on its decision-making, and awards that recognise the bad, the ugly and the good in 2023. Timeline 0:00 - 12:00 -...
18 Des 202356min

The 'Week in Review' - 8 December
More silence on a critical social issue. The report of the NDIS review delivers a range of recommendations, including the adoption of an evidence-based funding framework, but is it practical or even p...
8 Des 202330min

The 'Week in Review' - 1 December
We discuss the apparent reluctance to speak out on one important issue. The Government's entirely predictable response to the inquiry on access to new medicines and novel medical technologies, why dis...
1 Des 202337min

The 'Week in Review' - 24 November
The power of language and the habit governments have of weaponising the word 'sustainable'. How the term has been used to 'gently' justify breaking election commitments and its wider impact on policy ...
23 Nov 202335min



















